TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05800964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 305
Description: Short-term intravenous (IV) infusion
Study: NCT05766787

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide based contact lens cleaning and disinfecting solution

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide based contact lens cleaning and disinfecting solution
Study: NCT05753982

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiotape placement
Description: Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape placement
Description: Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.
Study: NCT05274191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate
Description: Pyrotinib ± standard regimen Pyrotinib: 400 mg/day (once a day, orally at the same time every day), continued until disease progression;
Study: NCT05930041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental CSP
Description: Either CSP is performed for 10-19 mm nonpedunculated colorectal polyps.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator HS-EMR
Description: Either HS-EMR is performed for 10-19 mm nonpedunculated colorectal polyps.
Study: NCT06419621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM8002
Description: PM8002 20 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20 mg/kg via IV infusion on Days 1 and 15 of each 28-day cycle
Study: NCT05980793

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PIP joint denervation
Description: Surgical denervation of the PIP joint

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient education plus exercise
Description: An education plus exercise program
Study: NCT04639947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeCheck
Description: EyeCheck is a newly developed device to provide intraocular pressure (IOP) measurements of the eyes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Tonometer (Goldmann and Tonopen)
Description: Standard of care intraocular pressures will be taken using the Goldmann and Tonopen to compare to the EyeCheck.
Study: NCT06238648

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and/or CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT and/or CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT04436029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Descartes 11
Description: Car T-cells
Study: NCT06406140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin tablets 500 mg
Description: tablets used to treat hyperphosphatemia and lower lipoprotein a concentration in End-Stage Renal Disease Patients Undergoing Hemodialysis
Study: NCT05413928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restrictive Eating- late
Description: Eating window will be 10 hours or less, starting 3 hours after waking up. Same monitoring as Baseline phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restrictive Eating- early
Description: Eating window will be 10 hours or less, starting 30 min after waking up. Same monitoring as Baseline phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restrictive Eating- early with early caloric intake
Description: Same as TRE-early, but concentrating caloric intake early in the eating window Same monitoring as Baseline phase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrient-controlled meals
Description: Meals with a determined amount of protein, carbohydrates, and fat.
Study: NCT05274191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard regimen
Description: standard regimen
Study: NCT03918577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric Vestibular Stimulation
Description: Cold water creates a convection current in the semicircular canal of the vestibular apparatus, leading to brief (\<3 min) and typically well tolerated sense of rotational movement. Similar stimulation is routinely used in standard vestibular diagnostic testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric Vestibular Stimulation
Description: Cold water creates a convection current in the semicircular canal of the vestibular apparatus, leading to brief (\<3 min) and typically well tolerated sense of rotational movement. Similar stimulation is routinely used in standard vestibular diagnostic testing.
Study: NCT05476536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-management skills and healthy technology APP
Description: self-management skills and healthy technology APP
Study: NCT06550687

Intervention type: OTHER
Group type: OTHER
Intervention: Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis
Description: Phase 1: Observation of doctor-patient consultations Phase 2: Adaptation of information tools Phase 3: Assessment of understanding of information tools

Intervention type: OTHER
Group type: OTHER
Intervention: Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis
Description: Phase 1: Observation of doctor-patient consultations Phase 2: Adaptation of information tools Phase 3: Assessment of understanding of information tools
Study: NCT04587791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400mg Cannabidiol
Description: Participants will receive 400mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 800mg Cannabidiol
Description: Participants will receive 800mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1200mg Cannabidiol
Description: Participants will receive 1200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Participants will receive saline
Study: NCT05654649

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
Study: NCT05576662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir
Description: Two 150 mg tablets taken by mouth every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: One 100 mg capsule taken by mouth every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ritonavir
Description: One 100 mg capsule taken by mouth every 12 hours
Study: NCT05164666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-103
Description: TAK-103 intravenous infusion
Study: NCT06180356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib oral tablets
Description: Niraparib 300 or 200 mg according to body weight or platelet count. Tablets will be taken orally, once daily, continuously (in 28-day cycles).
Study: NCT04942054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1
Description: Dose escalation cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2
Description: Pharmacodyanamic (PD) dose exploration cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 3
Description: Dose expansion at dose(s) ≤ maximum tolerated dose (MTD) cohort
Study: NCT05186454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone, morphine, midazolam
Description: 1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam
Study: NCT05492890

Intervention type: DEVICE
Intervention: Dexcom G6
Description: Continuous glucose monitoring
Study: NCT05536466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: bariatric surgery
Study: NCT05934773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KineAssist robotic treadmill
Description: A formal standardization procedure will be used. Prior to testing, the participant's weight, height, age, blood pressure, and resting heart rate will be recorded. Each session will take place over a 1 hour period. All of our participants will have 1 evaluation sessions prior to the training sessions (overground) and 1 evaluation sessions at the end of the training sessions (overground).~Each participant will have the training sessions up to 3 times each week. The total number of training sessions would be 12-16 sessions (based on duration of stay) of robotic treadmill training for, distributed equally over each specific training modality (Endurance x 4, Strength x 4, Speed x 4, and Dynamic Balance x 4).
Study: NCT06092710

Intervention type: DIAGNOSTIC_TEST
Intervention: neuro-sensorial subjective evaluation of the airways collapsibility
Description: verbal and manual guidance of subjects from a therapist to experiment the subjective perception of the air flow through their airways and airways collapsibility

Intervention type: DIAGNOSTIC_TEST
Intervention: neuro-sensorial subjective evaluation of the airways collapsibility
Description: verbal and manual guidance of subjects from a therapist to experiment the subjective perception of the air flow through their airways and airways collapsibility
Study: NCT05617339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I am (internet approach to migraine)
Description: I AM has a biopsychosocial perspective. Modules 1-3 and 10 are mandatory and for those who are in need of shorter support and module 1-10 is for those who have more frequent and severe migraines and want a long time of support and treatment. The rationale of the treatment assumes that we do not know why we get migraines and instead focus on becoming as good as possible at managing the migraine attacks. The focus area of the treatments cognitive-behavioral interventions is, among other things, psychoeducation, what migraine is and what happens in the body during migraines and pain, interpretation of symptoms and information processing, training to stop through mindfulness and becoming aware of assumptions that guide behavior during pain management, management of grief, worry, guilt and feelings of shame based on self-compassion, challenging avoidances in a valued direction through ACT interventions and physiotherapist-led cardio training and exercises.
Study: NCT05196594

Intervention type: DIAGNOSTIC_TEST
Intervention: collection of stools for genetic analysis
Description: Intestinal microbiome analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: collection of stools for genetic analysis
Description: Intestinal microbiome analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: collection of stools for genetic analysis
Description: Intestinal microbiome analysis
Study: NCT03897998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: 4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment.
Study: NCT05997758

Intervention type: OTHER
Intervention: SEEG stimulation
Description: Electrodes already implanted in patient's anterior insula will be stimulated below the patient-specific threshold at which a seizure was induced. This stimulations will coincide with certain trials in the adaptation task.

Intervention type: BEHAVIORAL
Intervention: Adaptation task
Description: Participants will perform a task that requires them to learn and correctly respond to outliers of two sorts; inconsequential outliers, which require no action, and outliers that are relevant to the course of stimuli and outcomes in future trials, requiring adaptive action.

Intervention type: BEHAVIORAL
Intervention: Adaptation task
Description: Participants will perform a task that requires them to learn and correctly respond to outliers of two sorts; inconsequential outliers, which require no action, and outliers that are relevant to the course of stimuli and outcomes in future trials, requiring adaptive action.
Study: NCT05184556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Description: FBT is a structured behavioral treatment focused on empowering caregivers to take charge of the adolescent's eating behavior and return him/her to a normative weight and developmental trajectory. FBT involves three consecutive phases: 1) caregivers are fully in control of the adolescent's eating; 2) control of eating is gradually returned to the adolescent; and 3) developmental issues are explored. In the current study, FBT is adapted for delivery in the home setting in the following ways: intensified dose of treatment (2-6 hours of therapy per week over 10 - 32 weeks); use of clinician as an additional support to the family; multiple family meals in the home and community; sociocultural tailoring; and inclusion of supplemental individual work with the adolescent to improve emotion regulation/distress tolerance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrative family therapy
Description: The integrated family therapy approach includes psychoeducation, supportive family therapy, and elements of cognitive-behavioral interventions. Families may be referred for additional nutritional counseling and prescribed a meal plan as indicated. Typical strategies include educating families on the presentation and prognosis of adolescent AN; identifying dysfunctional family structures/alliances and communication patterns; using reflective listening to engage and validate family members; challenging maladaptive beliefs about eating and weight; and supporting families in developing strategies for management of both general and eating disorder-specific distress. Treatment is generally non-directive.
Study: NCT05068024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FWD1509 MsOH
Description: FWD1509 MsOH is administered orally once daily. The starting dose is 10 mg/day for dose-escalation phase, and the dose level to be investigated in the expansion study will depend on the emerging data. For dose-extension phase, the recommended Phase 2 dose will be administered.
Study: NCT06407271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM custom ZrO2 healing abutment
Description: Application of custom, zirconium-dioxide healing abutment, fabricated with computer aided design and manufacturing, following immediate implantation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylindrical ZrO2 healing abutment
Description: Application of cylindrical, zirconium-dioxide healing abutment following immediate implantation.
Study: NCT05894655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) leading testing navigation and general preventive care reminders
Description: This strategy provides health counseling about when COVID-19 testing is recommended, which test to use, testing instructions, and how to interpret results. Community Health Workers (CHW) will also offer general preventive health care reminders such as flu shots, blood pressure checks, and A1c screenings. This strategy will be available full-time during the first 3 months of roll-out at each clinic and after 3 months, the CHW will be available as needed. Trained bilingual CHW will be supervised by a SYH employee.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) leading testing navigation and general preventive care reminders
Description: This strategy provides health counseling about when COVID-19 testing is recommended, which test to use, testing instructions, and how to interpret results. Community Health Workers (CHW) will also offer general preventive health care reminders such as flu shots, blood pressure checks, and A1c screenings. This strategy will be available full-time during the first 3 months of roll-out at each clinic and after 3 months, the CHW will be available as needed. Trained bilingual CHW will be supervised by a SYH employee.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) leading testing navigation and general preventive care reminders
Description: This strategy provides health counseling about when COVID-19 testing is recommended, which test to use, testing instructions, and how to interpret results. Community Health Workers (CHW) will also offer general preventive health care reminders such as flu shots, blood pressure checks, and A1c screenings. This strategy will be available full-time during the first 3 months of roll-out at each clinic and after 3 months, the CHW will be available as needed. Trained bilingual CHW will be supervised by a SYH employee.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Community Health Worker (CHW) leading testing navigation and general preventive care reminders
Description: This strategy provides health counseling about when COVID-19 testing is recommended, which test to use, testing instructions, and how to interpret results. Community Health Workers (CHW) will also offer general preventive health care reminders such as flu shots, blood pressure checks, and A1c screenings. This strategy will be available full-time during the first 3 months of roll-out at each clinic and after 3 months, the CHW will be available as needed. Trained bilingual CHW will be supervised by a SYH employee.
Study: NCT05419817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab is an immunotherapy (monoclonal antibodies) that will be given at a dosage of 200 mg IV, on Day 1 of each 21 day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: A small molecule inhibitor of multiple tyrosine kinases that will be taken at a dosage of 100 mg orally, every day
Study: NCT05058768

Intervention type: DIAGNOSTIC_TEST
Intervention: The lungs causes and extrapulmonary factors
Description: Acute lung injury due to internal and external pulmonary causes can be used as intervention items in this study, and intervention items can be excluded according to inclusion criteria and exclusion criteria.
Study: NCT05805813

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: peritoneal rest
Description: Change continuous ambulatory peritoneal dialysis to intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month. In this way, give a chance of peritoneum rest.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: peritoneal rest
Description: Change continuous ambulatory peritoneal dialysis to intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month. In this way, give a chance of peritoneum rest.
Study: NCT06024967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: PEG-somatropin
Study: NCT04660032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: An electronic prompt (nudge) will be sent to the participant's obstetric care provider. The provider will receive a staff message in Epic (Penn Chart) that his/her patient has an upcoming postpartum visit. The message will be sent 1 week before the scheduled visit. The message will have patient-specific information including hypertensive diagnosis, blood pressure medication(s), gestational diabetes diagnosis, and primary care provider as listed in the Epic banner. The message will also have dot phrases for recommended counseling and contact information for UPHS primary care and cardiology providers. There will be example text recommending follow-up with primary care or cardiology; counseling on risk of future CVD; and recommending aspirin in a future pregnancy.
Study: NCT05126212

Intervention type: OTHER
Intervention: User experience
Description: User experience is assessed by validated scale

Intervention type: OTHER
Intervention: User experience
Description: User experience is assessed by validated scale

Intervention type: OTHER
Intervention: User experience
Description: User experience is assessed by validated scale